Clinical Trial

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Study acronym: AmiCARE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.
Trial Details
NCT Number NCT07469488
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
Enrollment 122 participants
Start Date 2026-04-30
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13